Trial Radar KI
Die klinische Studie NCT03635112 (DIONE) für Crohn-Krankheit ist abgebrochen. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE) Phase 2 167

Abgebrochen
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT03635112 (DIONE) untersucht Behandlung im Zusammenhang mit Crohn-Krankheit. Diese interventionsstudie der Phase 2 hat den Status abgebrochen und startete am 19. November 2018. Es ist geplant, 167 Teilnehmer aufzunehmen. Durchgeführt von Theravance Biopharma wird der Abschluss für 30. Dezember 2021 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 13. März 2023 aktualisiert.
Kurzbeschreibung
A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.
Ausführliche Beschreibung
A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 12 weeks of induction therapy with TD˗1473 in subjects with moderately-to-severely active Crohn's Disease. This study includes 3 phases: Screening, Induction, and Active Treatment Extension (ATE). The Induction phase of the study is a randomized, double blind, placebo controlled, parallel ...Mehr anzeigen
Offizieller Titel

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease

Erkrankungen
Crohn-Krankheit
Weitere Studien-IDs
  • DIONE
  • 0173
  • 2018-001272-37 (EudraCT-Nummer)
NCT-Nummer
Studienbeginn (tatsächlich)
2018-11-19
Zuletzt aktualisiert
2023-03-13
Studienende (vorauss.)
2021-12-30
Geplante Rekrutierung
167
Studientyp
Interventionsstudie
PHASE
Phase 2
Status
Abgebrochen
Stichwörter
TD-1473
Janus kinase inhibitor
JAK inhibitor
Inflammatory Bowel Disease
IBD
Crohn's Disease
Intestinal restriction
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Vierfach verblindet
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Aktives VergleichspräparatActive Treatment TD-1473 with Dose A
1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.
TD-1473
TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Aktives VergleichspräparatActive Treatment TD-1473 with Dose B
1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks.
TD-1473
TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Placebo-VergleichspräparatPlacebo
1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.
PLACEBO
Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
TD-1473
TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: \<150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and \>450, very severe disease.
Baseline to Week 12
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Number of Participants Who Demonstrated a Clinical Response as Measured by CDAI
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: \<150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and \>450, very severe disease. Clinical response was defined as a reduction from baseline of ≥100 points or CDAI \<150
Week 12
Number of Participants Who Demonstrated CDAI Clinical Remission
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Benchmarks for disease activity as measured by the CDAI were: \<150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and \>450, very severe disease. CDAI clinical remission was defined as a CDAI score less than 150 at Week 12.
Week 12
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12
The SES-CD incorporated 4 descriptors: the ulcer size, the proportion of surface covered by ulcer, the proportion of surface covered by other lesions, and the presence of stenosis. Each descriptor was scored in 5 segments (ileum, right colon, transverse colon, left colon, and rectum). The total score ranged from 0 to 56, with higher scores indicating a worse outcome.
Baseline to Week 12
Number of Participants With Endoscopic Response at Week 12
Endoscopic Response was defined as a reduction of SES-CD score or Endoscopic Remission (defined as SES-CD ≤ 2) at Week 12.
Week 12
Number of Participants With Stool Frequency and Abdominal Pain (SFAP) Clinical Remission
SFAP clinical remission was defined as an abdominal pain score ≤1 (on a scale of 0-3 with 0 representing 'no pain' and 3 representing 'severe pain'), stool frequency ≤2.8, and both not worse than baseline at Week 12.
Week 12
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
  • Is at least 18 years of age at screening
  • Males and females with clinical evidence of Crohn's disease for at least 3 months duration at screening
  • Moderately-to-severely active Crohn's Disease at baseline, as defined by a Crohn's Disease Activity Index (CDAI) score of 220-450 inclusive
  • SES-CD score of ≥ 3 with ulceration (corresponding to a score of 1) in at least 1 of the 5 ileocolonic segments on the Ulcerated Surface subscore of the SES-CD]
  • Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to conventional therapy (aminosalicylates, corticosteroids and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate) or biologics (e.g., anti-TNF therapy, anti-IL-12/23 (anti-interleukin), anti-integrin).
  • Additional inclusion criteria apply

  • Is currently receiving biologic (anti-TNF, anti-integrin, or anti-IL12/23) therapy
  • Has a current bacterial, parasitic, fungal, or viral infection
  • Has clinically significant abnormalities in laboratory evaluations
  • Prior exposure or potential exposure to a JAK inhibitor that was stopped due to intolerance or lack of efficacy
  • Subject has participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to Screening or 5x the half-life of the investigational drug, whichever is longer, or is currently participating in another trial of an investigational drug (or medical device)
  • Subject has failed ≥ 3 biologic agents of 3 different mechanisms of action (i.e., anti-TNF, anti-integrin, and anti-IL12/23)
  • Additional exclusion criteria apply
Theravance Biopharma logoTheravance Biopharma
Keine Kontaktdaten vorhanden
178 Studienstandorte in 22 Ländern

Bavaria

Theravance Biopharma Investigational Site, München, Bavaria, 80331, Germany
Theravance Biopharma Investigational Site, München, Bavaria, 81377, Germany

Lower Saxony

Theravance Biopharma Investigational Site, Hanover, Lower Saxony, 30625, Germany

Schleswig-Holstein

Theravance Biopharma Investigational Site, Kiel, Schleswig-Holstein, 24105, Germany
Theravance Biopharma Investigational Site, Berlin, 14050, Germany
Theravance Biopharma Investigational Site, Hamburg, 22559, Germany

Carinthia

Theravance Biopharma Investigational Site, Klagenfurt, Carinthia, 9020, Austria

Tyrol

Theravance Biopharma Investigational Site, Innsbruck, Tyrol, 6020, Austria

Vienna

Theravance Biopharma Investigational Site, Vienna, Vienna, 1090, Austria

Alabama

Theravance Biopharma Investigational Site, Birmingham, Alabama, 35233-2110, United States
Theravance Biopharma Investigational Site, Mobile, Alabama, 36688, United States

Arizona

Theravance Biopharma Investigational Site, Scottsdale, Arizona, 85259-5499, United States

California

Theravance Biopharma Investigational Site, La Jolla, California, 92093, United States
Theravance Biopharma Investigational Site, Los Angeles, California, 90048, United States
Theravance Biopharma Investigational Site, Oakland, California, 94612, United States
Theravance Biopharma Investigational Site, Santa Monica, California, 90404, United States

Florida

Theravance Biopharma Investigational Site, Aventura, Florida, 33180, United States
Theravance Biopharma Investigational Site, Clearwater, Florida, 33765, United States
Theravance Biopharma Investigational Site, Hialeah, Florida, 33013, United States
Theravance Biopharma Investigational Site, Hollywood, Florida, 33021, United States
Theravance Biopharma Investigational Site, Largo, Florida, 33777, United States
Theravance Biopharma Investigational Site, Miami, Florida, 33135, United States
Theravance Biopharma Investigational Site, New Port Richey, Florida, 34653, United States
Theravance Biopharma Investigational Site, St. Petersburg, Florida, 33710, United States
Theravance Biopharma Investigational Site, Tampa, Florida, 33603, United States
Theravance Biopharma Investigational Site, Tampa, Florida, 33606, United States

Illinois

Theravance Biopharma Investigational Site, New Lenox, Illinois, 60451, United States

Kansas

Theravance Biopharma Investigational Site, Kansas City, Kansas, 66160, United States

Kentucky

Theravance Biopharma Investigational Site, Louisville, Kentucky, 40202, United States

Maryland

Theravance Biopharma Investigational Site, Rockville, Maryland, 20850, United States

Massachusetts

Theravance Biopharma Investigational Site, Brockton, Massachusetts, 02302, United States

Michigan

Theravance Biopharma Investigational Site, Wyoming, Michigan, 49519, United States

Missouri

Theravance Biopharma Investigational Site, St Louis, Missouri, 63110, United States

Nevada

Theravance Biopharma Investigational Site, Las Vegas, Nevada, 89133, United States

New York

Theravance Biopharma Investigational Site, Utica, New York, 13502, United States

North Carolina

Theravance Biopharma Investigational Site, Gastonia, North Carolina, 28504, United States
Theravance Biopharma Investigational Site, Greenville, North Carolina, 27834, United States
PMG Research of Salisbury, Salisbury, North Carolina, 28144, United States

Oklahoma

Theravance Biopharma Investigational Site, Tulsa, Oklahoma, 74136, United States

Pennsylvania

Theravance Biopharma Investigational Site, Pittsburgh, Pennsylvania, 15212, United States
Theravance Biopharma Investigational Site, Uniontown, Pennsylvania, 15401, United States

South Carolina

Theravance Biopharma Investigational Site, Orangeburg, South Carolina, 29118, United States
Theravance Biopharma Investigational Site, Rock Hill, South Carolina, 29732, United States

Texas

Theravance Biopharma Investigational Site, Boerne, Texas, 78006, United States
Theravance Biopharma Investigational Site, El Paso, Texas, 79936, United States
Theravance Biopharma Investigational Site, Garland, Texas, 75044, United States
Theravance Biopharma Investigational Site, Harlingen, Texas, 78550, United States
Theravance Biopharma Investigational Site, Houston, Texas, 77058, United States
Theravance Biopharma Investigational Site, San Antonio, Texas, 78215, United States
Theravance Biopharma Investigational Site, San Antonio, Texas, 78229, United States
Theravance Biopharma Investigational Site, Southlake, Texas, 76092, United States
Theravance Biopharma Investigational Site, Spring, Texas, 77386, United States

Virginia

Theravance Biopharma Investigational Site, Lansdowne Town Center, Virginia, 20176, United States

New South Wales

Theravance Biopharma Investigational Site, Bankstown, New South Wales, 2200, Australia

South Australia

Theravance Biopharma Investigational Site, Elizabeth Vale, South Australia, 5112, Australia

Western Australia

Theravance Biopharma Investigational Site, Perth, Western Australia, 6000, Australia

Sofia

Theravance Biopharma Investigational Site, Sofia, Sofia, 1303, Bulgaria
Theravance Biopharma Investigational Site, Sofia, Sofia, 1336, Bulgaria
Theravance Biopharma Investigational Site, Sofia, Sofia, 1431, Bulgaria
Theravance Biopharma Investigational Site, Sofia, Sofia, 1527, Bulgaria
Theravance Biopharma Investigational Site, Sofia, Sofia, 1784, Bulgaria

Targovishte

Theravance Biopharma Investigational Site, Targovishte, Targovishte, 7700, Bulgaria
Theravance Biopharma Investigational Site, Dobrich, 9300, Bulgaria
Theravance Biopharma Investigational Site, Plovdiv, 4004, Bulgaria
Theravance Biopharma Investigational Site, Sliven, 8800, Bulgaria
Theravance Biopharma Investigational Site, Stara Zagora, 6000, Bulgaria
Theravance Biopharma Investigational Site, Stara Zagora, 6001, Bulgaria
Theravance Biopharma Investigational Site, Veliko Tarnovo, 5000, Bulgaria

County of Osijek-Baranja

Theravance Biopharma Investigational Site, Osijek, County of Osijek-Baranja, 31 000, Croatia
Theravance Biopharma Investigational Site, Rijeka, 51000, Croatia
Theravance Biopharma Investigational Site, Split, 21000, Croatia
Theravance Biopharma Investigational Site, Zagreb, 10000, Croatia

Auvergne-Rhône-Alpes

Theravance Biopharma Investigational Site, Pierre-Bénite, Auvergne-Rhône-Alpes, 69495, France

Auvergne

Theravance Biopharma Investigational Site, Saint-Etienne, Auvergne, 42055, France

Champagne-ardenne

Theravance Biopharma Investigational Site, Reims, Champagne-ardenne, 51092, France

Midi-pyrenees

Theravance Biopharma Investigational Site, Toulouse, Midi-pyrenees, 31059, France

Provence-Alpes-Côte d'Azur Region

Theravance Biopharma Investigational Site, Nice, Provence-Alpes-Côte d'Azur Region, 06202, France
Theravance Biopharma Investigational Site, Clichy, 92110, France
Theravance Biopharma Investigational Site, Vandœuvre-lès-Nancy, 54511, France

Île-de-France Region

Theravance Biopharma Investigational Site, Colombes, Île-de-France Region, 92701, France
Theravance Biopharma Investigational Site, Tbilisi, 0114, Georgia
Theravance Biopharma Investigational Site, Tbilisi, 0159, Georgia

Attica

Theravance Biopharma Investigational Site, Athens, Attica, 115 27, Greece

Crete

Theravance Biopharma Investigational Site, Heraklion, Crete, 71110, Greece

Bács-Kiskun county

Theravance Biopharma Investigational Site, Baja, Bács-Kiskun county, 6500, Hungary

Hajdú-Bihar

Theravance Biopharma Investigational Site, Debrecen, Hajdú-Bihar, 4032, Hungary

Heves County

Theravance Biopharma Investigational Site, Gyöngyös, Heves County, 3200, Hungary
Theravance Biopharma Investigational Site, Budapest, H-1088, Hungary

Rehoboth

Theravance Biopharma Investigational Site, Be’er Ya‘aqov, Rehoboth, 7030000, Israel
Theravance Biopharma Investigational Site, Rehovot, Rehoboth, 7661041, Israel

Sharon

Theravance Biopharma Investigational Site, Kfar Saba, Sharon, 4428164, Israel
Theravance Biopharma Investigational Site, Haifa, 3339419, Israel
Theravance Biopharma Investigational Site, Holon, 5822012, Israel
Theravance Biopharma Investigational Site, Jerusalem, 9362410, Israel
Theravance Biopharma Investigational Site, Nahariya, 2210001, Israel
Theravance Biopharma Investigational Site, Petah Tikva, 4941492, Israel
Theravance Biopharma Investigational Site, Tel Aviv, 6423906, Israel

Waikato Region

Theravance Biopharma Investigational Site, Hamilton, Waikato Region, 3204, New Zealand

Wellington Region

Theravance Biopharma Investigational Site, Lower Hutt, Wellington Region, 5010, New Zealand

Greater Poland Voivodeship

Theravance Biopharma Investigational Site, Poznan, Greater Poland Voivodeship, 61-113, Poland

Kuyavian-Pomeranian Voivodeship

Theravance Biopharma Investigational Site, Włocławek, Kuyavian-Pomeranian Voivodeship, 87-800, Poland

Lesser Poland Voivodeship

Theravance Biopharma Investigational Site, Krakow, Lesser Poland Voivodeship, 31501, Poland

Lower Silesian Voivodeship

Theravance Biopharma Investigational Site, Wroclaw, Lower Silesian Voivodeship, 52416, Poland
Theravance Biopharma Investigational Site, Wroclaw, Lower Silesian Voivodeship, 53-333, Poland

Masovian Voivodeship

Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 00-728, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 00635, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 02-653, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 02-781, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 03-580, Poland

Podkarpackie Voivodeship

Theravance Biopharma Investigational Site, Rzeszów, Podkarpackie Voivodeship, 35302, Poland

Pomeranian Voivodeship

Theravance Biopharma Investigational Site, Sopot, Pomeranian Voivodeship, 81-756, Poland

Silesian Voivodeship

Theravance Biopharma Investigational Site, Tychy, Silesian Voivodeship, 43 100, Poland

Zachodnio-Pomorskie

Theravance Biopharma Investigational Site, Szczecin, Zachodnio-Pomorskie, 71434, Poland

Łódź Voivodeship

Theravance Biopharma Investigational Site, Lodz, Łódź Voivodeship, 90302, Poland
Theravance Biopharma Investigational Site, Lodz, Łódź Voivodeship, 91-034, Poland
Theravance Biopharma Investigational Site, Lodz, Łódź Voivodeship, 91363, Poland
Theravance Biopharma Investigational Site, Braga, 4700-308, Portugal
Theravance Biopharma Investigational Site, Guimarães, 4835-044, Portugal
Theravance Biopharma Investigational Site, Leiria, 2410-197, Portugal
Theravance Biopharma Investigational Site, Lisbon, 1500-458, Portugal
Theravance Biopharma Investigational Site, Santa Maria da Feira, 4520-211, Portugal
Theravance Biopharma Investigational Site, Setúbal, 2910-446, Portugal
Theravance Biopharma Investigational Site, Vila Nova de Gaia, 4434-502, Portugal

Bihor County

Theravance Biopharma Investigational Site, Oradea, Bihor County, 410066, Romania

București

Theravance Biopharma Investigational Site, Bucharest, București, 020125, Romania

Cluj

Theravance Biopharma Investigational Site, Cluj-Napoca, Cluj, 400162, Romania

Timiș County

Theravance Biopharma Investigational Site, Timișoara, Timiș County, 300002, Romania
Theravance Biopharma Investigational Site, Timișoara, Timiș County, 300167, Romania
Theravance Biopharma Investigational Site, Bucharest, 050098, Romania
Theravance Biopharma Investigational Site, Cluj-Napoca, 400006, Romania

Moscow City

Theravance Biopharma Investigational Site, Moscow, Moscow City, 127015, Russia

Rostov Oblast

Theravance Biopharma Investigational Site, Rostov-on-Don, Rostov Oblast, 344022, Russia

Samara Oblast

Theravance Biopharma Investigational Site, Samara, Samara Oblast, 443041, Russia
Theravance Biopharma Investigational Site, Novosibirsk, 630005, Russia
Theravance Biopharma Investigational Site, Novosibirsk, 630087, Russia
Theravance Biopharma Investigational Site, Saint Petersburg, 195257, Russia
Theravance Biopharma Investigational Site, Saint Petersburg, 196247, Russia
Theravance Biopharma Investigational Site, Saratov, 410053, Russia
Theravance Biopharma Investigational Site, Belgrade, 11000, Serbia
Theravance Biopharma Investigational Site, Belgrade, 11080, Serbia
Theravance Biopharma Investigational Site, Kragujevac, 34000, Serbia
Theravance Biopharma Investigational Site, Niš, 18000, Serbia
Theravance Biopharma Investigational Site, Subotica, 24000, Serbia
Theravance Biopharma Investigational Site, Zrenjanin, 23000, Serbia

Gauteng

Theravance Biopharma Investigational Site, Johannesburg, Gauteng, 1619, South Africa
Theravance Biopharma Investigational Site, Johannesburg, Gauteng, 2196, South Africa
Theravance Biopharma Investigational Site, Lenasia, Gauteng, 1827, South Africa

Western Cape

Theravance Biopharma Investigational Site, Claremont, Western Cape, 7708, South Africa

Gangwon-do

Theravance Biopharma Investigational Site, Wŏnju, Gangwon-do, 26426, South Korea

Gyeonggi-do

Theravance Biopharma Investigational Site, Guri-si, Gyeonggi-do, 11923, South Korea
Theravance Biopharma Investigational Site, Seongnam-si, Gyeonggi-do, 13496, South Korea
Theravance Biopharma Investigational Site, Busan, 48108, South Korea
Theravance Biopharma Investigational Site, Daegu, 42601, South Korea
Theravance Biopharma Investigational Site, Seoul, 02447, South Korea
Theravance Biopharma Investigational Site, Seoul, 03722, South Korea

Las Palmas

Theravance Biopharma Investigational Site, Las Palmas de Gran Canaria, Las Palmas, 35010, Spain
Theravance Biopharma Investigational Site, Barcelona, 08022, Spain
Theravance Biopharma Investigational Site, Barcelona, 08036, Spain
Theravance Biopharma Investigational Site, Huelva, 21005, Spain
Theravance Biopharma Investigational Site, Madrid, 28922, Spain
Theravance Biopharma Investigational Site, Valencia, 46010, Spain

KIEV CITY

Theravance Biopharma Investigational Site, Kiev, KIEV CITY, 04107, Ukraine
Theravance Biopharma Investigational Site, Kyiv, KIEV CITY, 01030, Ukraine

Kyiv City

Theravance Biopharma Investigational Site, Kyiv, Kyiv City, 01133, Ukraine

Poltava Oblast

Theravance Biopharma Investigational Site, Kremenchuk, Poltava Oblast, 39617, Ukraine

Transcarpathian

Theravance Biopharma Investigational Site, Uzhhorod, Transcarpathian, 88000, Ukraine

Zakarpattia Oblast

Theravance Biopharma Investigational Site, Uzhhorod, Zakarpattia Oblast, 88009, Ukraine
Theravance Biopharma Investigational Site, Chernivtsi, 58001, Ukraine
Theravance Biopharma Investigational Site, Kharkiv, 61037, Ukraine
Theravance Biopharma Investigational Site, Kharkiv, 61039, Ukraine
Theravance Biopharma Investigational Site, Kharkiv, 61137, Ukraine
Theravance Biopharma Investigational Site, Lviv, 79059, Ukraine
Theravance Biopharma Investigational Site, Vinnytsia, 21005, Ukraine
Theravance Biopharma Investigational Site, Zaporizhzhya, 69104, Ukraine
Theravance Biopharma Investigational Site, Zaporizhzhya, 69600, Ukraine

England

Theravance Biopharma Investigational Site, Blackpool, England, FY3 8NR, United Kingdom
Theravance Biopharma Investigational Site, London, England, NW1 2PG, United Kingdom

Scotland

Theravance Biopharma Investigational Site, Glasgow, Scotland, G51 4TF, United Kingdom